

Diego Centonze

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6410630/publications.pdf>

Version: 2024-02-01

439
papers

26,306
citations

5558

82
h-index

12233

133
g-index

447
all docs

447
docs citations

447
times ranked

24389
citing authors

#	ARTICLE	IF	CITATIONS
1	Different Susceptibility of T and B Cells to Cladribine Depends On Their Levels of Deoxycytidine Kinase Activity Linked to Activation Status. <i>Journal of NeuroImmune Pharmacology</i> , 2022, 17, 195-205.	2.1	10
2	MiR-142-3p regulates synaptopathy-driven disease progression in multiple sclerosis. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	13
3	Pivotal Trials in Multiple Sclerosis: Similarities Prove Not to Be Useful. <i>Neurology and Therapy</i> , 2022, 11, 1-8.	1.4	3
4	Multiple sclerosis: Inflammation, autoimmunity and plasticity. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2022, 184, 457-470.	1.0	9
5	Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis. <i>Biomolecules</i> , 2022, 12, 222.	1.8	21
6	The BDNF Val66Met Polymorphism (rs6265) Modulates Inflammation and Neurodegeneration in the Early Phases of Multiple Sclerosis. <i>Genes</i> , 2022, 13, 332.	1.0	5
7	Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	9
8	Multifocal Electroretinogram Photopic Negative Response: A Reliable Paradigm to Detect Localized Retinal Ganglion Cells™ Impairment in Retrobulbar Optic Neuritis Due to Multiple Sclerosis as a Model of Retinal Neurodegeneration. <i>Diagnostics</i> , 2022, 12, 1156.	1.3	3
9	Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. <i>Journal of Neurology</i> , 2022, 269, 5382-5394.	1.8	32
10	Interleukin 6 SNP rs1818879 Regulates Radiological and Inflammatory Activity in Multiple Sclerosis. <i>Genes</i> , 2022, 13, 897.	1.0	3
11	Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2151-2153.	1.4	7
12	Preventive exercise attenuates IL-2-driven mood disorders in multiple sclerosis. <i>Neurobiology of Disease</i> , 2022, 172, 105817.	2.1	8
13	Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 2238-2245.	1.8	15
14	Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1939-1947.	1.4	13
15	The microRNA let-7b-5p Is Negatively Associated with Inflammation and Disease Severity in Multiple Sclerosis. <i>Cells</i> , 2021, 10, 330.	1.8	24
16	Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus. <i>Journal of Neurology</i> , 2021, 268, 1540-1543.	1.8	4
17	Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance. <i>Multiple Sclerosis Journal</i> , 2021, 27, 989-1001.	1.4	13
18	Drugs used in the treatment of multiple sclerosis during COVID-19 pandemic: a critical viewpoint. <i>Current Neuropharmacology</i> , 2021, 19, .	1.4	5

#	ARTICLE	IF	CITATIONS
19	COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. <i>CNS Drugs</i> , 2021, 35, 317-330.	2.7	89
20	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. <i>Journal of Neurology</i> , 2021, 268, 3961-3968.	1.8	47
21	Macrophage Plasticity and Polarization Are Altered in the Experimental Model of Multiple Sclerosis. <i>Biomolecules</i> , 2021, 11, 837.	1.8	22
22	Assessment of Macular Function by Multifocal Electroretinogram in Patients with Multiple Sclerosis Treated with Fingolimod. <i>Advances in Therapy</i> , 2021, 38, 3986-3996.	1.3	2
23	Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential. <i>Immunity</i> , 2021, 54, 1543-1560.e6.	6.6	42
24	Time for a new deal between neurology and psychoanalysis. <i>Brain</i> , 2021, 144, 2228-2230.	3.7	2
25	COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 102983.	0.9	25
26	Cerebrospinal fluid levels of L-glutamate signal central inflammatory neurodegeneration in multiple sclerosis. <i>Journal of Neurochemistry</i> , 2021, 159, 857-866.	2.1	7
27	Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients. <i>Neurotherapeutics</i> , 2021, 18, 2598-2607.	2.1	12
28	Age at Disease Onset Associates With Oxidative Stress, Neuroinflammation, and Impaired Synaptic Plasticity in Relapsing-Remitting Multiple Sclerosis. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 694651.	1.7	9
29	Exercise protects from hippocampal inflammation and neurodegeneration in experimental autoimmune encephalomyelitis. <i>Brain, Behavior, and Immunity</i> , 2021, 98, 13-27.	2.0	22
30	Effects of Prismatic Lenses on Lateral Axial Dystonia in Parkinson's Disease: A Pilot Study. <i>Innovations in Clinical Neuroscience</i> , 2021, 18, 39-42.	0.1	0
31	Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110582.	1.5	9
32	Case Report: Overlap Between Long COVID and Functional Neurological Disorders. <i>Frontiers in Neurology</i> , 2021, 12, 811276.	1.1	8
33	Sleep Disorders in Patients With Craniopharyngioma: A Physiopathological and Practical Update. <i>Frontiers in Neurology</i> , 2021, 12, 817257.	1.1	7
34	Theoretical and Therapeutic Implications of the Spasticity-Plus Syndrome Model in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 802918.	1.1	7
35	Oral D-Aspartate enhances synaptic plasticity reserve in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 304-311.	1.4	13
36	Peripheral T cells from multiple sclerosis patients trigger synaptotoxic alterations in central neurons. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 160-170.	1.8	17

#	ARTICLE	IF	CITATIONS
37	Obesity worsens central inflammation and disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1237-1246.	1.4	72
38	Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study. <i>Journal of Neurology</i> , 2020, 267, 694-702.	1.8	6
39	Italian consensus on treatment of spasticity in multiple sclerosis. <i>European Journal of Neurology</i> , 2020, 27, 445-453.	1.7	20
40	"Prototypical" proinflammatory cytokine (IL-1) in multiple sclerosis: role in pathogenesis and therapeutic targeting. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 37-46.	1.5	16
41	Practice-dependent motor cortex plasticity is reduced in non-disabled multiple sclerosis patients. <i>Clinical Neurophysiology</i> , 2020, 131, 566-573.	0.7	13
42	Modeling Resilience to Damage in Multiple Sclerosis: Plasticity Meets Connectivity. <i>International Journal of Molecular Sciences</i> , 2020, 21, 143.	1.8	9
43	A Single Nucleotide ADA Genetic Variant Is Associated to Central Inflammation and Clinical Presentation in MS: Implications for Cladribine Treatment. <i>Genes</i> , 2020, 11, 1152.	1.0	5
44	Emerging Role of Extracellular Vesicles in the Pathophysiology of Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7336.	1.8	39
45	Interleukin-1 ² Alters Hebbian Synaptic Plasticity in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6982.	1.8	9
46	Re-Examining the Role of TNF in MS Pathogenesis and Therapy. <i>Cells</i> , 2020, 9, 2290.	1.8	52
47	Specific dietary interventions to tackle obesity should be a routine part of recommended MS care "Yes. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1627-1629.	1.4	2
48	Therapeutic interventions for Pisa syndrome in idiopathic Parkinson's disease. A Scoping Systematic Review. <i>Clinical Neurology and Neurosurgery</i> , 2020, 198, 106242.	0.6	9
49	Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 914-920.	0.9	5
50	Myasthenia Gravis Associated With SARS-CoV-2 Infection. <i>Annals of Internal Medicine</i> , 2020, 173, 1027-1028.	2.0	128
51	Functional Assessment of Outer and Middle Macular Layers in Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2020, 9, 3766.	1.0	7
52	Morphological Outer Retina Findings in Multiple Sclerosis Patients With or Without Optic Neuritis. <i>Frontiers in Neurology</i> , 2020, 11, 858.	1.1	6
53	Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642097083.	1.5	5
54	Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction. <i>Haematologica</i> , 2020, 105, 2056-2070.	1.7	70

#	ARTICLE	IF	CITATIONS
55	Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis. <i>Cells</i> , 2020, 9, 1290.	1.8	23
56	A Dynamic Splicing Program Ensures Proper Synaptic Connections in the Developing Cerebellum. <i>Cell Reports</i> , 2020, 31, 107703.	2.9	25
57	Moving exercise research in multiple sclerosis forward (the MoXFo initiative): Developing consensus statements for research. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1303-1308.	1.4	46
58	IL-6 in the Cerebrospinal Fluid Signals Disease Activity in Multiple Sclerosis. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 120.	1.8	32
59	Inflammation-Associated Synaptic Alterations as Shared Threads in Depression and Multiple Sclerosis. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 169.	1.8	35
60	Inflammation and Corticospinal Functioning in Multiple Sclerosis: A TMS Perspective. <i>Frontiers in Neurology</i> , 2020, 11, 566.	1.1	14
61	Expert opinion on the use of cladribine tablets in clinical practice. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642093501.	1.5	23
62	Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study). <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102124.	0.9	18
63	Advances in physical rehabilitation of multiple sclerosis. <i>Current Opinion in Neurology</i> , 2020, 33, 255-261.	1.8	20
64	CSF Levels of the Endocannabinoid Anandamide are Reduced in Patients with Untreated Narcolepsy Type 1: A Pilot Study. <i>CNS and Neurological Disorders - Drug Targets</i> , 2020, 19, 142-147.	0.8	4
65	Interleukin-6 Disrupts Synaptic Plasticity and Impairs Tissue Damage Compensation in Multiple Sclerosis. <i>Neurorehabilitation and Neural Repair</i> , 2019, 33, 825-835.	1.4	26
66	The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray). <i>PLoS ONE</i> , 2019, 14, e0219670.	1.1	7
67	Fingolimod Immune Effects Beyond Its Sequestration Ability. <i>Neurology and Therapy</i> , 2019, 8, 231-240.	1.4	22
68	Treatment with Dimethyl Fumarate Enhances Cholinergic Transmission in Multiple Sclerosis. <i>CNS Drugs</i> , 2019, 33, 1133-1139.	2.7	7
69	Beyond rehabilitation in MS: Insights from non-invasive brain stimulation. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1363-1371.	1.4	28
70	Immunomodulatory Effects of Exercise in Experimental Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2019, 10, 2197.	2.2	33
71	Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care. <i>Advances in Therapy</i> , 2019, 36, 3238-3252.	1.3	20
72	IFN β enhances mesenchymal stromal (Stem) cells immunomodulatory function through STAT1-3 activation and mTOR-associated promotion of glucose metabolism. <i>Cell Death and Disease</i> , 2019, 10, 85.	2.7	34

#	ARTICLE	IF	CITATIONS
73	Predictors of Evolution Into Multiple Sclerosis After a First Acute Demyelinating Syndrome in Children and Adolescents. <i>Frontiers in Neurology</i> , 2019, 9, 1156.	1.1	12
74	The Characterization of Regulatory T-Cell Profiles in Alzheimer's Disease and Multiple Sclerosis. <i>Scientific Reports</i> , 2019, 9, 8788.	1.6	90
75	Subclinical dysphagia in task-specific mouth tremor triggered by drinking. <i>Clinical Neurophysiology</i> , 2019, 130, 1289-1291.	0.7	1
76	Distinct Expression of Inflammatory Features in T Helper 17 Cells from Multiple Sclerosis Patients. <i>Cells</i> , 2019, 8, 533.	1.8	14
77	Voluntary running wheel attenuates motor deterioration and brain damage in cuprizone-induced demyelination. <i>Neurobiology of Disease</i> , 2019, 129, 102-117.	2.1	42
78	A pilot study on the efficacy of transcranial direct current stimulation applied to the pharyngeal motor cortex for dysphagia associated with brainstem involvement in multiple sclerosis. <i>Clinical Neurophysiology</i> , 2019, 130, 1017-1024.	0.7	17
79	Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and α -synuclein-related neurodegenerative disorders: A brain [18F]FDG PET study. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 97-105.	1.1	22
80	Transient Receptor Potential Vanilloid 1 Modulates Central Inflammation in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 30.	1.1	33
81	Sleep Complaints, Sleep and Breathing Disorders in Myotonic Dystrophy Type 2. <i>Current Neurology and Neuroscience Reports</i> , 2019, 19, 9.	2.0	11
82	Synaptic Plasticity Shapes Brain Connectivity: Implications for Network Topology. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6193.	1.8	78
83	The Italian multiple sclerosis register. <i>Neurological Sciences</i> , 2019, 40, 155-165.	0.9	59
84	Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 261-267.	0.9	22
85	The cross-cultural adaptation and psychometric validation of the MSSS-88 for use in Italian patients with multiple sclerosis. <i>Disability and Rehabilitation</i> , 2019, 41, 465-471.	0.9	2
86	PDGF Modulates Synaptic Excitability and Short-Latency Afferent Inhibition in Multiple Sclerosis. <i>Neurochemical Research</i> , 2019, 44, 726-733.	1.6	5
87	The Link Among Neurological Diseases: Extracellular Vesicles as a Possible Brain Injury Footprint. <i>NeuroSignals</i> , 2019, 27, 25-39.	0.5	13
88	Fingolimod reduces the clinical expression of active demyelinating lesions in MS. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 215-219.	0.9	5
89	Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. <i>Journal of Neurology</i> , 2018, 265, 828-835.	1.8	45
90	Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leucoencephalopathy patients? Comment on "Guidelines on the use of therapeutic apheresis in clinical practice" evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue. <i>Journal of Clinical Apheresis</i> , 2018, 33, 450-451.	0.7	2

#	ARTICLE	IF	CITATIONS
91	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet</i> , The, 2018, 391, 1263-1273.	6.3	684
92	Can pharmacological manipulation of LTP favor the effects of motor rehabilitation in multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , 2018, 24, 902-907.	1.4	5
93	The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases. <i>Progress in Neurobiology</i> , 2018, 160, 82-100.	2.8	104
94	Nerve growth factor is elevated in the CSF of patients with multiple sclerosis and central neuropathic pain. <i>Journal of Neuroimmunology</i> , 2018, 314, 89-93.	1.1	10
95	Restless legs syndrome is highly prevalent in patients with postpolio syndrome. <i>Sleep Medicine</i> , 2018, 41, 112.	0.8	0
96	Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 153-160.	0.9	101
97	Abnormal cervical lymph nodes in multiple sclerosis: a preliminary ultrasound study. <i>Radiologia Medica</i> , 2018, 123, 202-208.	4.7	5
98	Letter to the Editor Regarding: A Comprehensive Review on Copemyl®. <i>Neurology and Therapy</i> , 2018, 7, 385-390.	1.4	1
99	AMBRA1 Controls Regulatory T-Cell Differentiation and Homeostasis Upstream of the FOXO3-FOXP3 Axis. <i>Developmental Cell</i> , 2018, 47, 592-607.e6.	3.1	34
100	Exploiting the Multifaceted Effects of Cannabinoids on Mood to Boost Their Therapeutic Use Against Anxiety and Depression. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 424.	1.4	34
101	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. <i>Journal of Neurology</i> , 2018, 265, 2851-2860.	1.8	43
102	Multiple sclerosis and fabry Disease, two sides of the coin? The case of an Italian family. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, 164-167.	0.9	4
103	Comparative Sleep Disturbances in Myotonic Dystrophy Types 1 and 2. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 102.	2.0	19
104	Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2665-2675.	2.0	36
105	Multiple Sclerosis: kFLC index values related to gender. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, 58-60.	0.9	1
106	Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course. <i>Journal of Neurology</i> , 2018, 265, 2540-2547.	1.8	38
107	Effectiveness of Physiotherapy Interventions on Spasticity in People With Multiple Sclerosis. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2018, 97, 793-807.	0.7	38
108	Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1272-1278.	0.9	10

#	ARTICLE	IF	CITATIONS
109	Tumor Necrosis Factor and Interleukin-1 β Modulate Synaptic Plasticity during Neuroinflammation. <i>Neural Plasticity</i> , 2018, 2018, 1-12.	1.0	149
110	Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study. <i>CNS Drugs</i> , 2018, 32, 963-970.	2.7	35
111	Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake. <i>Journal of Neuroinflammation</i> , 2018, 15, 5.	3.1	25
112	Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2018, 15, 108.	3.1	22
113	Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive Functions. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 238.	1.7	82
114	Fingolimod vs dimethyl fumarate in multiple sclerosis. <i>Neurology</i> , 2018, 91, e153-e161.	1.5	35
115	Mitochondrial Serine Protease HTRA2 p.G399S in a Female with Di George Syndrome and Parkinson's Disease. <i>Parkinson's Disease</i> , 2018, 2018, 1-6.	0.6	2
116	No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. <i>Neurology</i> , 2017, 88, 1144-1152.	1.5	57
117	Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 443-455.	1.3	66
118	Cannabinoids in Parkinson's Disease. <i>Cannabis and Cannabinoid Research</i> , 2017, 2, 21-29.	1.5	71
119	Neurophysiology of synaptic functioning in multiple sclerosis. <i>Clinical Neurophysiology</i> , 2017, 128, 1148-1157.	0.7	50
120	KFLC Index utility in multiple sclerosis diagnosis: Further confirmation. <i>Journal of Neuroimmunology</i> , 2017, 309, 31-33.	1.1	31
121	Heart rate variability is differentially altered in multiple sclerosis: implications for acute, worsening and progressive disability. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017, 3, 205521731770131.	0.5	20
122	TRPV1 polymorphisms and risk of interferon β -induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2017, 305, 172-174.	1.1	5
123	miR-142-3p Is a Key Regulator of IL-1 β -Dependent Synaptopathy in Neuroinflammation. <i>Journal of Neuroscience</i> , 2017, 37, 546-561.	1.7	88
124	Effects of postural exercises in patients with Parkinson's disease and Pisa syndrome: A pilot study. <i>NeuroRehabilitation</i> , 2017, 41, 423-428.	0.5	13
125	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). <i>Journal of Neurology</i> , 2017, 264, 2436-2449.	1.8	44
126	Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis. <i>Neurology</i> , 2017, 89, 1338-1347.	1.5	118

#	ARTICLE	IF	CITATIONS
127	Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy. <i>Neuroepidemiology</i> , 2017, 48, 171-178.	1.1	6
128	Interferon- β causes mood abnormalities by altering cannabinoid CB1 receptor function in the mouse striatum. <i>Neurobiology of Disease</i> , 2017, 108, 45-53.	2.1	11
129	A novel crosstalk within the endocannabinoid system controls GABA transmission in the striatum. <i>Scientific Reports</i> , 2017, 7, 7363.	1.6	46
130	Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration. <i>Metabolism: Clinical and Experimental</i> , 2017, 77, 39-46.	1.5	67
131	The still under-investigated role of cognitive deficits in PML diagnosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017, 2, .	1.1	4
132	Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis. <i>Journal of Neurology</i> , 2017, 264, 284-294.	1.8	44
133	Remodeling Functional Connectivity in Multiple Sclerosis: A Challenging Therapeutic Approach. <i>Frontiers in Neuroscience</i> , 2017, 11, 710.	1.4	15
134	Amyloid- β Homeostasis Bridges Inflammation, Synaptic Plasticity Deficits and Cognitive Dysfunction in Multiple Sclerosis. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 390.	1.4	21
135	Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study. <i>PLoS ONE</i> , 2017, 12, e0165415.	1.1	5
136	Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). <i>PLoS ONE</i> , 2017, 12, e0180651.	1.1	24
137	miR-142-3p Is a Key Regulator of IL-1 β -Dependent Synaptopathy in Neuroinflammation. <i>Journal of Neuroscience</i> , 2017, 37, 546-561.	1.7	10
138	Caspase-8 contributes to angiogenesis and chemotherapy resistance in glioblastoma. <i>ELife</i> , 2017, 6, .	2.8	47
139	Management Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a. <i>International Journal of MS Care</i> , 2016, 18, 211-218.	0.4	18
140	Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2016, 13, 207.	3.1	127
141	Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory. <i>PLoS ONE</i> , 2016, 11, e0160261.	1.1	46
142	Disability and Fatigue Can Be Objectively Measured in Multiple Sclerosis. <i>PLoS ONE</i> , 2016, 11, e0148997.	1.1	28
143	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 944-951.	0.9	88
144	Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β -1a using an electronic device: the RIVER study. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 931-935.	2.4	16

#	ARTICLE	IF	CITATIONS
145	The importance of a multi-disciplinary perspective and patient activation programmes in MS management. <i>Multiple Sclerosis Journal</i> , 2016, 22, 34-46.	1.4	44
146	Modulation of monocytes by bioactive lipid anandamide in multiple sclerosis involves distinct Toll-like receptors. <i>Pharmacological Research</i> , 2016, 113, 313-319.	3.1	22
147	Neural Stem Cell Transplantation Induces Stroke Recovery by Upregulating Glutamate Transporter GLT-1 in Astrocytes. <i>Journal of Neuroscience</i> , 2016, 36, 10529-10544.	1.7	91
148	Interaction between interleukin-1 β and type-1 cannabinoid receptor is involved in anxiety-like behavior in experimental autoimmune encephalomyelitis. <i>Journal of Neuroinflammation</i> , 2016, 13, 231.	3.1	35
149	The heritage of glatiramer acetate and its use in multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016, 1, .	1.1	14
150	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. <i>Journal of Neurology</i> , 2016, 263, 1727-1735.	1.8	45
151	RANTES correlates with inflammatory activity and synaptic excitability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1405-1412.	1.4	46
152	Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances. <i>Neurological Sciences</i> , 2016, 37, 437-442.	0.9	7
153	Epigenetic modifications of Dexras 1 along the nNOS pathway in an animal model of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016, 294, 32-40.	1.1	6
154	Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems. <i>Journal of Neurology</i> , 2016, 263, 751-759.	1.8	35
155	Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression. <i>Journal of Neuroinflammation</i> , 2016, 13, 36.	3.1	54
156	Linking synaptopathy and gray matter damage in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 146-149.	1.4	18
157	T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis. <i>Clinical Science</i> , 2015, 129, 291-303.	1.8	55
158	The p38 mitogen-activated protein kinase cascade modulates T helper type 17 differentiation and functionality in multiple sclerosis. <i>Immunology</i> , 2015, 146, 251-263.	2.0	24
159	Exploring the role of microglia in mood disorders associated with experimental multiple sclerosis. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 243.	1.8	15
160	Treatment Decisions for Patients With Active Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 387.	4.5	3
161	FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients. <i>Cell Death and Disease</i> , 2015, 6, e1741-e1741.	2.7	28
162	Dopaminergic dysfunction is associated with IL-1 β -dependent mood alterations in experimental autoimmune encephalomyelitis. <i>Neurobiology of Disease</i> , 2015, 74, 347-358.	2.1	42

#	ARTICLE	IF	CITATIONS
163	Subclinical central inflammation is risk for RIS and CIS conversion to MS. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1443-1452.	1.4	58
164	The autonomic balance predicts cardiac responses after the first dose of fingolimod. <i>Multiple Sclerosis Journal</i> , 2015, 21, 206-216.	1.4	29
165	Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 202-218.	0.9	85
166	Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1713-1722.	1.4	23
167	IL-1 β Dependent Cerebellar Synaptopathy in a Mouse Model of Multiple Sclerosis. <i>Cerebellum</i> , 2015, 14, 19-22.	1.4	26
168	Reversible hyporegenerative anemia during natalizumab treatment. <i>Multiple Sclerosis Journal</i> , 2015, 21, 257-258.	1.4	5
169	Role of amyloid- β CSF levels in cognitive deficit in MS. <i>Clinica Chimica Acta</i> , 2015, 449, 23-30.	0.5	27
170	Paroxysmal dysarthria-ataxia syndrome resolving after fingolimod treatment. <i>Journal of the Neurological Sciences</i> , 2015, 350, 101-102.	0.3	7
171	Epstein-Barr virus genetic variants are associated with multiple sclerosis. <i>Neurology</i> , 2015, 84, 1362-1368.	1.5	44
172	Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. <i>Acta Neuropathologica</i> , 2015, 130, 279-295.	3.9	160
173	Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2015, 11, 711-724.	4.9	204
174	Placebo Effects in a Multiple Sclerosis Spasticity Enriched Clinical Trial with the Oromucosal Cannabinoid Spray (Δ^9 -THC/ Δ^9 -CBD): Dimension and Possible Causes. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 215-221.	1.9	10
175	The interplay between inflammatory cytokines and the endocannabinoid system in the regulation of synaptic transmission. <i>Neuropharmacology</i> , 2015, 96, 105-112.	2.0	27
176	Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene. <i>PLoS ONE</i> , 2015, 10, e0135441.	1.1	3
177	Behavioral and electrophysiological effects of endocannabinoid and dopaminergic systems on salient stimuli. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 183.	1.0	9
178	Interleukin-1 β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53. <i>Molecular Neurodegeneration</i> , 2014, 9, 56.	4.4	78
179	K Index in cerebrospinal fluid: a valid tool in multiple sclerosis diagnosis. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 2014, 10, 167-171.	0.2	1
180	Free D-aspartate regulates neuronal dendritic morphology, synaptic plasticity, gray matter volume and brain activity in mammals. <i>Translational Psychiatry</i> , 2014, 4, e417-e417.	2.4	47

#	ARTICLE	IF	CITATIONS
181	CB1 receptor affects cortical plasticity and response to physiotherapy in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014, 1, e48.	3.1	17
182	Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 851-858.	0.9	101
183	Functional connectivity changes within specific networks parallel the clinical evolution of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1050-1057.	1.4	47
184	Advances in the Management of Multiple Sclerosis Spasticity: Multiple Sclerosis Spasticity Nervous Pathways. <i>European Neurology</i> , 2014, 72, 6-8.	0.6	11
185	Cortical plasticity predicts recovery from relapse in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 451-457.	1.4	63
186	From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study. <i>European Neurology</i> , 2014, 71, 233-241.	0.6	4
187	Pre- and postsynaptic type-1 cannabinoid receptors control the alterations of glutamate transmission in experimental autoimmune encephalomyelitis. <i>Neuropharmacology</i> , 2014, 79, 567-572.	2.0	28
188	Interleukin-1 β Promotes Long-Term Potentiation in Patients with Multiple Sclerosis. <i>NeuroMolecular Medicine</i> , 2014, 16, 38-51.	1.8	64
189	Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. <i>Neurological Sciences</i> , 2014, 35, 307-316.	0.9	30
190	Disability in multiple sclerosis: When synaptic long-term potentiation fails. <i>Neuroscience and Biobehavioral Reviews</i> , 2014, 43, 88-99.	2.9	32
191	Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 276, 229-231.	1.1	28
192	Interleukin-8 is associated with acute and persistent dysfunction after optic neuritis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1841-1850.	1.4	17
193	Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. <i>Multiple Sclerosis Journal</i> , 2014, 20, 304-312.	1.4	117
194	Synaptic plasticity in multiple sclerosis and in experimental autoimmune encephalomyelitis. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2014, 369, 20130162.	1.8	43
195	Treatment Options to Reduce Disease Activity After Natalizumab: Paradoxical Effects of Corticosteroids. <i>CNS Neuroscience and Therapeutics</i> , 2014, 20, 748-753.	1.9	10
196	CD19 as a molecular target in CNS autoimmunity. <i>Acta Neuropathologica</i> , 2014, 128, 177-190.	3.9	22
197	Growth Factors and Synaptic Plasticity in Relapsing-Remitting Multiple Sclerosis. <i>NeuroMolecular Medicine</i> , 2014, 16, 490-498.	1.8	18
198	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. <i>BMC Neurology</i> , 2014, 14, 65.	0.8	47

#	ARTICLE	IF	CITATIONS
199	Cerebrospinal fluid detection of interleukin-1 β in phase of remission predicts disease progression in multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2014, 11, 32.	3.1	70
200	Phlebographic Study Does Not Show Differences Between Patients with MS and Control Subjects. <i>American Journal of Neuroradiology</i> , 2014, 35, 1174-1179.	1.2	0
201	Effect of glatiramer acetate on disease reactivation in <sc>MS</sc> patients discontinuing natalizumab. <i>European Journal of Neurology</i> , 2013, 20, 87-94.	1.7	41
202	Interleukin-1 β Alters Glutamate Transmission at Purkinje Cell Synapses in a Mouse Model of Multiple Sclerosis. <i>Journal of Neuroscience</i> , 2013, 33, 12105-12121.	1.7	125
203	<i>InÂvitro</i> and <i>inÂvivo</i> models of <sc>H</sc>untington's disease show alterations in the endocannabinoid system. <i>FEBS Journal</i> , 2013, 280, 3376-3388.	2.2	37
204	Future MS care: a consensus statement of the MS in the 21st Century Steering Group. <i>Journal of Neurology</i> , 2013, 260, 462-469.	1.8	27
205	Glatiramer Acetate Protects Against Inflammatory Synaptopathy in Experimental Autoimmune Encephalomyelitis. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 651-663.	2.1	22
206	Pharyngeal Electrical Stimulation for Dysphagia Associated with Multiple Sclerosis: A Pilot Study. <i>Brain Stimulation</i> , 2013, 6, 418-423.	0.7	50
207	Interleukin-1 β alters the sensitivity of cannabinoid CB1 receptors controlling glutamate transmission in the striatum. <i>Neuroscience</i> , 2013, 250, 232-239.	1.1	33
208	Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1084-1094.	1.4	43
209	Anatomical brain connectivity can assess cognitive dysfunction in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1161-1168.	1.4	33
210	A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. <i>Multiple Sclerosis Journal</i> , 2013, 19, 59-68.	1.4	21
211	Transcranial Direct Current Stimulation Ameliorates Tactile Sensory Deficit in Multiple Sclerosis. <i>Brain Stimulation</i> , 2013, 6, 654-659.	0.7	54
212	Effects of endocannabinoid and endovanilloid systems on aversive memory extinction. <i>Behavioural Brain Research</i> , 2013, 256, 101-107.	1.2	47
213	Cladribine interferes with IL-1 β synaptic effects in experimental multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2013, 264, 8-13.	1.1	23
214	Short interval intracortical facilitation correlates with the degree of disability inÂmultiple sclerosis. <i>Brain Stimulation</i> , 2013, 6, 67-71.	0.7	34
215	Determination of kFLC and K Index in cerebrospinal fluid: A valid alternative to assess intrathecal immunoglobulin synthesis. <i>Journal of Neuroimmunology</i> , 2013, 263, 116-120.	1.1	66
216	Abnormal <sc>NMDA</sc> receptor function exacerbates experimental autoimmune encephalomyelitis. <i>British Journal of Pharmacology</i> , 2013, 168, 502-517.	2.7	39

#	ARTICLE	IF	CITATIONS
217	Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1508-1517.	1.4	42
218	Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis. <i>PLoS Pathogens</i> , 2013, 9, e1003220.	2.1	132
219	Synaptic Plasticity and PDGF Signaling Defects Underlie Clinical Progression in Multiple Sclerosis. <i>Journal of Neuroscience</i> , 2013, 33, 19112-19119.	1.7	70
220	Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. <i>Annals of Neurology</i> , 2013, 73, 626-636.	2.8	83
221	Oxidative modifications of cerebral transthyretin are associated with multiple sclerosis. <i>Proteomics</i> , 2013, 13, 1002-1009.	1.3	22
222	Inflammation Subverts Hippocampal Synaptic Plasticity in Experimental Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e54666.	1.1	123
223	Association between a Genetic Variant of Type-1 Cannabinoid Receptor and Inflammatory Neurodegeneration in Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e82848.	1.1	21
224	Opposite Roles of NMDA Receptors in Relapsing and Primary Progressive Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e67357.	1.1	29
225	Brain Hemodynamic Changes Associated with Chronic Cerebrospinal Venous Insufficiency Are Not Specific to Multiple Sclerosis and Do Not Increase Its Severity. <i>Radiology</i> , 2012, 265, 233-239.	3.6	42
226	Severe relapses under fingolimod treatment prescribed after natalizumab. <i>Neurology</i> , 2012, 79, 2004-2005.	1.5	55
227	Prevalence and Management of Panic Attacks during Infliximab Infusion in Psoriatic Patients. <i>Dermatology</i> , 2012, 225, 236-241.	0.9	5
228	Subventricular zone neural progenitors protect striatal neurons from glutamatergic excitotoxicity. <i>Brain</i> , 2012, 135, 3320-3335.	3.7	67
229	TNF- α -mediated anxiety in a mouse model of multiple sclerosis. <i>Experimental Neurology</i> , 2012, 237, 296-303.	2.0	126
230	Neuroprotection of kaempferol by autophagy in models of rotenone-mediated acute toxicity: possible implications for Parkinson's disease. <i>Neurobiology of Aging</i> , 2012, 33, 767-785.	1.5	202
231	Effects of palmitoylation of Cys ⁴¹⁵ in helix 8 of the CB ₁ cannabinoid receptor on membrane localization and signalling. <i>British Journal of Pharmacology</i> , 2012, 165, 2635-2651.	2.7	50
232	Interleukin-1 β Causes Anxiety by Interacting with the Endocannabinoid System. <i>Journal of Neuroscience</i> , 2012, 32, 13896-13905.	1.7	96
233	Patient adherence to and tolerability of self-administered interferon β -1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. <i>BMC Neurology</i> , 2012, 12, 7.	0.8	50
234	TRPV1 Channels Regulate Cortical Excitability in Humans. <i>Journal of Neuroscience</i> , 2012, 32, 873-879.	1.7	75

#	ARTICLE	IF	CITATIONS
235	Inflammation inhibits GABA transmission in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1633-1635.	1.4	74
236	Differences in Spontaneously Avoiding or Approaching Mice Reflect Differences in CB1-Mediated Signaling of Dorsal Striatal Transmission. <i>PLoS ONE</i> , 2012, 7, e33260.	1.1	11
237	Prevalence study of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: preliminary data. <i>Radiologia Medica</i> , 2012, 117, 855-864.	4.7	12
238	LETTER TO THE EDITOR. <i>Brain Pathology</i> , 2012, 22, 79-79.	2.1	1
239	Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis. <i>British Journal of Pharmacology</i> , 2012, 165, 861-869.	2.7	67
240	GABAergic signaling and connectivity on Purkinje cells are impaired in experimental autoimmune encephalomyelitis. <i>Neurobiology of Disease</i> , 2012, 46, 414-424.	2.1	41
241	Interleukin-1 β causes synaptic hyperexcitability in multiple sclerosis. <i>Annals of Neurology</i> , 2012, 71, 76-83.	2.8	178
242	Early treatment with high-dose interferon beta-1a reverses cognitive and cortical plasticity deficits in multiple sclerosis. <i>Functional Neurology</i> , 2012, 27, 163-8.	1.3	33
243	Painful and involuntary multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 763-777.	0.9	11
244	Potential role of IL-13 in neuroprotection and cortical excitability regulation in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1301-1312.	1.4	54
245	Impaired inter-hemispheric facilitatory connectivity in schizophrenia. <i>Clinical Neurophysiology</i> , 2011, 122, 512-517.	0.7	18
246	Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 947-956.	2.0	90
247	Cannabinoid CB1 receptors regulate neuronal TNF- α effects in experimental autoimmune encephalomyelitis. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 1242-1248.	2.0	64
248	Loss of striatal cannabinoid CB1 receptor function in attention-deficit/hyperactivity disorder mice with point mutation of the dopamine transporter. <i>European Journal of Neuroscience</i> , 2011, 34, 1369-1377.	1.2	23
249	Functional characterization of putative cholesterol binding sequence (CRAC) in human type 1 cannabinoid receptor. <i>Journal of Neurochemistry</i> , 2011, 116, 858-865.	2.1	88
250	Cannabinoid receptor signalling in neurodegenerative diseases: a potential role for membrane fluidity disturbance. <i>British Journal of Pharmacology</i> , 2011, 163, 1379-1390.	2.7	37
251	Before or after does it matter? Different protocols of environmental enrichment differently influence motor, synaptic and structural deficits of cerebellar origin. <i>Neurobiology of Disease</i> , 2011, 42, 9-20.	2.1	35
252	Transient receptor potential vanilloid 1 channels modulate the synaptic effects of TNF- α and of IL-1 β in experimental autoimmune encephalomyelitis. <i>Neurobiology of Disease</i> , 2011, 43, 669-677.	2.1	56

#	ARTICLE	IF	CITATIONS
253	Transcranial magnetic stimulation primes the effects of exercise therapy in multiple sclerosis. <i>Journal of Neurology</i> , 2011, 258, 1281-1287.	1.8	107
254	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group of the Italian Neurological Society. <i>Neurological Sciences</i> , 2011, 32, 351-358.	0.9	17
255	Proposed chronic cerebrospinal venous insufficiency criteria do not predict multiple sclerosis risk or severity. <i>Annals of Neurology</i> , 2011, 70, 52-59.	2.8	89
256	Genetic variants of the NMDA receptor influence cortical excitability and plasticity in humans. <i>Journal of Neurophysiology</i> , 2011, 106, 1637-1643.	0.9	57
257	The (AAT) _n repeat of the cannabinoid CB ₁ receptor gene influences disease progression in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 281-288.	1.4	24
258	Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGNitive) Trial. <i>Multiple Sclerosis</i> , 2011, 17, 1071-1081.	1.1	10
259	Cognitive and Cortical Plasticity Deficits Correlate with Altered Amyloid- β CSF Levels in Multiple Sclerosis. <i>Neuropsychopharmacology</i> , 2011, 36, 559-568.	2.8	95
260	Risk of acute promyelocytic leukemia in multiple sclerosis. <i>Neurology</i> , 2011, 76, 1059-1065.	1.5	37
261	T Regulatory Cells Are Markers of Disease Activity in Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2011, 6, e21386.	1.1	64
262	Cognitive deficits in experimental autoimmune encephalomyelitis: neuroinflammation and synaptic degeneration. <i>Neurological Sciences</i> , 2010, 31, 255-259.	0.9	65
263	Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. <i>Annals of Neurology</i> , 2010, 68, 409-411.	2.8	40
264	Effects of caffeine on striatal neurotransmission: Focus on cannabinoid CB ₁ receptors. <i>Molecular Nutrition and Food Research</i> , 2010, 54, 525-531.	1.5	13
265	Effects of intermittent theta burst stimulation on spasticity in patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2010, 17, 295-300.	1.7	104
266	The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. <i>Cell Death and Differentiation</i> , 2010, 17, 1083-1091.	5.0	161
267	Preservation of Striatal Cannabinoid CB ₁ Receptor Function Correlates with the Antianxiety Effects of Fatty Acid Amide Hydrolase Inhibition. <i>Molecular Pharmacology</i> , 2010, 78, 260-268.	1.0	73
268	Brain-Derived Neurotrophic Factor Controls Cannabinoid CB ₁ Receptor Function in the Striatum. <i>Journal of Neuroscience</i> , 2010, 30, 8127-8137.	1.7	59
269	Multiparametric MR investigation of the motor pyramidal system in patients with "truly benign" multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 178-188.	1.4	12
270	Differential patterns of interhemispheric functional disconnection in mild and advanced multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1308-1316.	1.4	21

#	ARTICLE	IF	CITATIONS
271	Role of Aberrant Striatal Dopamine D ₁ Receptor/cAMP/Protein Kinase A/DARPP32 Signaling in the Paradoxical Calming Effect of Amphetamine. <i>Journal of Neuroscience</i> , 2010, 30, 11043-11056.	1.7	66
272	Voluntary Exercise and Sucrose Consumption Enhance Cannabinoid CB1 Receptor Sensitivity in the Striatum. <i>Neuropsychopharmacology</i> , 2010, 35, 374-387.	2.8	74
273	Abnormal mGlu 5 Receptor/Endocannabinoid Coupling in Mice Lacking FMRP and BC1 RNA. <i>Neuropsychopharmacology</i> , 2010, 35, 1500-1509.	2.8	104
274	Protein profiling of Guillain-Barré syndrome cerebrospinal fluid by two-dimensional electrophoresis and mass spectrometry. <i>Neuroscience Letters</i> , 2010, 485, 49-54.	1.0	28
275	Abnormal activity of the Na/Ca exchanger enhances glutamate transmission in experimental autoimmune encephalomyelitis. <i>Brain, Behavior, and Immunity</i> , 2010, 24, 1379-1385.	2.0	26
276	Transient receptor potential vanilloid 1 channels control acetylcholine/2-arachidonoylglycerol coupling in the striatum. <i>Neuroscience</i> , 2010, 167, 864-871.	1.1	33
277	The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. <i>Experimental Neurology</i> , 2010, 224, 92-102.	2.0	63
278	Effects of Anodal Transcranial Direct Current Stimulation on Chronic Neuropathic Pain in Patients With Multiple Sclerosis. <i>Journal of Pain</i> , 2010, 11, 436-442.	0.7	215
279	Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2010, 11, 83-90.	2.3	20
280	The use of repetitive transcranial magnetic stimulation (rTMS) for the treatment of spasticity. <i>Progress in Brain Research</i> , 2009, 175, 429-439.	0.9	57
281	Inflammation Triggers Synaptic Alteration and Degeneration in Experimental Autoimmune Encephalomyelitis. <i>Journal of Neuroscience</i> , 2009, 29, 3442-3452.	1.7	331
282	Abnormal brain lateralization and connectivity in Schizophrenia. <i>Reviews in the Neurosciences</i> , 2009, 20, 61-70.	1.4	59
283	Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. <i>Multiple Sclerosis Journal</i> , 2009, 15, 779-788.	1.4	172
284	D-Aspartate: An Atypical Amino Acid with Neuromodulatory Activity in Mammals. <i>Reviews in the Neurosciences</i> , 2009, 20, 429-40.	1.4	30
285	ALTERED ANANDAMIDE DEGRADATION IN ATTENTION-DEFICIT/HYPERACTIVITY DISORDER. <i>Neurology</i> , 2009, 72, 1526-1527.	1.5	25
286	Antiaquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1153-1163.	1.4	63
287	Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis. <i>Neurobiology of Disease</i> , 2009, 36, 51-59.	2.1	108
288	Cannabis-based treatment induces polarity-reversing plasticity assessed by theta burst stimulation in humans. <i>Brain Stimulation</i> , 2009, 2, 229-233.	0.7	24

#	ARTICLE	IF	CITATIONS
289	Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. <i>Neurological Sciences</i> , 2009, 30, 531-534.	0.9	45
290	Adaptations of Striatal Endocannabinoid System During Stress. <i>Molecular Neurobiology</i> , 2009, 39, 178-184.	1.9	7
291	Lipid rafts regulate 2-araachidonoylglycerol metabolism and physiological activity in the striatum. <i>Journal of Neurochemistry</i> , 2009, 109, 371-381.	2.1	44
292	Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. <i>European Journal of Neurology</i> , 2009, 16, 360-366.	1.7	66
293	Caffeine drinking potentiates cannabinoid transmission in the striatum: Interaction with stress effects. <i>Neuropharmacology</i> , 2009, 56, 590-597.	2.0	23
294	TRPV1 channels facilitate glutamate transmission in the striatum. <i>Molecular and Cellular Neurosciences</i> , 2009, 40, 89-97.	1.0	124
295	A Substrate Trapping Mutant Form of Striatal-Enriched Protein Tyrosine Phosphatase Prevents Amphetamine-Induced Stereotypies and Long-Term Potentiation in the Striatum. <i>Biological Psychiatry</i> , 2009, 65, 637-645.	0.7	24
296	Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone. <i>Leukemia and Lymphoma</i> , 2009, 50, 1217-1218.	0.6	5
297	Abnormal parieto-motor connectivity in Tuberous Sclerosis Complex. <i>Epilepsy Research</i> , 2009, 87, 102-105.	0.8	8
298	Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. <i>Nature Neuroscience</i> , 2008, 11, 152-159.	7.1	276
299	Adaptations of glutamatergic synapses in the striatum contribute to recovery from cerebellar damage. <i>European Journal of Neuroscience</i> , 2008, 27, 2188-2196.	1.2	25
300	Abnormal Striatal GABA Transmission in the Mouse Model for the Fragile X Syndrome. <i>Biological Psychiatry</i> , 2008, 63, 963-973.	0.7	157
301	Connectivity Between Posterior Parietal Cortex and Ipsilateral Motor Cortex Is Altered in Schizophrenia. <i>Biological Psychiatry</i> , 2008, 64, 815-819.	0.7	51
302	Increased levels of d-aspartate in the hippocampus enhance LTP but do not facilitate cognitive flexibility. <i>Molecular and Cellular Neurosciences</i> , 2008, 37, 236-246.	1.0	79
303	The GTP-binding protein Rhes modulates dopamine signalling in striatal medium spiny neurons. <i>Molecular and Cellular Neurosciences</i> , 2008, 37, 335-345.	1.0	68
304	NF-kB/NOS cross-talk induced by mitochondrial complex II inhibition: Implications for Huntington's disease. <i>Neuroscience Letters</i> , 2008, 434, 241-246.	1.0	40
305	Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal cells. <i>Neuropharmacology</i> , 2008, 54, 45-50.	2.0	46
306	Improvement of hand dexterity following motor cortex rTMS in multiple sclerosis patients with cerebellar impairment. <i>Multiple Sclerosis Journal</i> , 2008, 14, 995-998.	1.4	61

#	ARTICLE	IF	CITATIONS
307	Chronic Psychoemotional Stress Impairs Cannabinoid-Receptor-Mediated Control of GABA Transmission in the Striatum. <i>Journal of Neuroscience</i> , 2008, 28, 7284-7292.	1.7	101
308	d-Aspartate Prevents Corticostriatal Long-Term Depression and Attenuates Schizophrenia-Like Symptoms Induced by Amphetamine and MK-801. <i>Journal of Neuroscience</i> , 2008, 28, 10404-10414.	1.7	106
309	Early relapses after the first dose of natalizumab in active multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1137-1138.	1.4	11
310	The Endocannabinoid System in Peripheral Lymphocytes as a Mirror of Neuroinflammatory Diseases. <i>Current Pharmaceutical Design</i> , 2008, 14, 2370-2382.	0.9	83
311	The Brain Cytoplasmic RNA BC1 Regulates Dopamine D2 Receptor-Mediated Transmission in the Striatum. <i>Journal of Neuroscience</i> , 2007, 27, 8885-8892.	1.7	46
312	Mechanisms of Disease: basic-research-driven investigations in humans—the case of hyperkinetic disorders. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 572-580.	2.7	15
313	Effects of motor cortex rTMS on lower urinary tract dysfunction in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 269-271.	1.4	86
314	Na ⁺ /Ca ²⁺ Exchanger Maintains Ionic Homeostasis in the Peri-Infarct Area. <i>Stroke</i> , 2007, 38, 1614-1620.	1.0	11
315	The (Endo)Cannabinoid System in Multiple Sclerosis and Amyotrophic Lateral Sclerosis. <i>International Review of Neurobiology</i> , 2007, 82, 171-186.	0.9	24
316	The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. <i>Brain</i> , 2007, 130, 2543-2553.	3.7	185
317	Repetitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis. <i>Neurology</i> , 2007, 68, 1045-1050.	1.5	152
318	Saving the Ischemic Penumbra: Potential Role for Statins and Phosphodiesterase Inhibitors. <i>Current Vascular Pharmacology</i> , 2007, 5, 259-265.	0.8	9
319	Expression of ectonucleotidase CD39 by Foxp3 ⁺ Treg cells: hydrolysis of extracellular ATP and immune suppression. <i>Blood</i> , 2007, 110, 1225-1232.	0.6	1,074
320	The endocannabinoid system in targeting inflammatory neurodegenerative diseases. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 180-187.	4.0	165
321	The endocannabinoid pathway in Huntington's disease: A comparison with other neurodegenerative diseases. <i>Progress in Neurobiology</i> , 2007, 81, 349-379.	2.8	109
322	Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. <i>Neuropharmacology</i> , 2007, 53, 783-789.	2.0	53
323	Endocannabinoids limit metabotropic glutamate 5 receptor-mediated synaptic inhibition of striatal principal neurons. <i>Molecular and Cellular Neurosciences</i> , 2007, 35, 302-310.	1.0	34
324	Chronic cocaine sensitizes striatal GABAergic synapses to the stimulation of cannabinoid CB1 receptors. <i>European Journal of Neuroscience</i> , 2007, 25, 1631-1640.	1.2	37

#	ARTICLE	IF	CITATIONS
325	Synaptic plasticity during recovery from permanent occlusion of the middle cerebral artery. <i>Neurobiology of Disease</i> , 2007, 27, 44-53.	2.1	63
326	Low frequency rTMS of the SMA transiently ameliorates peak-dose LID in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2006, 117, 1917-1921.	0.7	85
327	Chronic Cocaine Prevents Depotentiation at Corticostriatal Synapses. <i>Biological Psychiatry</i> , 2006, 60, 436-443.	0.7	43
328	NR2B-containing NMDA receptors promote the neurotoxic effects of 3-nitropropionic acid but not of rotenone in the striatum. <i>Experimental Neurology</i> , 2006, 202, 470-479.	2.0	27
329	L-DOPA treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinases. <i>Neuroscience Letters</i> , 2006, 398, 211-214.	1.0	18
330	Deficits of glutamate transmission in the striatum of toxic and genetic models of Huntington's disease. <i>Neuroscience Letters</i> , 2006, 410, 6-10.	1.0	15
331	Distinct roles for spinophilin and neurabin in dopamine-mediated plasticity. <i>Neuroscience</i> , 2006, 140, 897-911.	1.1	84
332	Deficits of glutamate transmission in the striatum of experimental hemiballism. <i>Neuroscience</i> , 2006, 143, 213-221.	1.1	7
333	NR2B Subunit Exerts a Critical Role in Postischemic Synaptic Plasticity. <i>Stroke</i> , 2006, 37, 1895-1901.	1.0	63
334	Removing Pathogenic Memories: A Neurobiology of Psychotherapy. <i>Molecular Neurobiology</i> , 2005, 32, 123-132.	1.9	50
335	CSF from MS patients can induce acute conduction block in the isolated optic nerve. <i>European Journal of Neurology</i> , 2005, 12, 45-48.	1.7	5
336	Improvement of choreic movements by 1Hz repetitive transcranial magnetic stimulation in Huntington's disease patients. <i>Annals of Neurology</i> , 2005, 58, 655-656.	2.8	49
337	Striatal synaptic plasticity: Implications for motor learning and Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 395-402.	2.2	141
338	rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease. <i>Neurology</i> , 2005, 65, 623-625.	1.5	139
339	Pathological Synaptic Plasticity in the Striatum: Implications for Parkinson's Disease. <i>NeuroToxicology</i> , 2005, 26, 779-783.	1.4	80
340	Modulatory action of metabotropic glutamate receptor (mGluR) 5 on mGluR1 function in striatal cholinergic interneurons. <i>Neuropharmacology</i> , 2005, 49, 104-113.	2.0	64
341	Long-term potentiation and memory processes in the psychological works of Sigmund Freud and in the formation of neuropsychiatric symptoms. <i>Neuroscience</i> , 2005, 130, 559-565.	1.1	6
342	Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism. <i>Neuroscience</i> , 2005, 133, 831-840.	1.1	54

#	ARTICLE	IF	CITATIONS
343	Abnormal Sensitivity to Cannabinoid Receptor Stimulation Might Contribute to Altered Gamma-Aminobutyric Acid Transmission in the Striatum of R6/2 Huntington's Disease Mice. <i>Biological Psychiatry</i> , 2005, 57, 1583-1589.	0.7	79
344	Cortical hyperexcitability in post-traumatic stress disorder secondary to minor accidental head trauma: a neurophysiologic study. <i>Journal of Psychiatry and Neuroscience</i> , 2005, 30, 127-32.	1.4	17
345	Engagement of Rat Striatal Neurons by Cortical Epileptiform Activity Investigated With Paired Recordings. <i>Journal of Neurophysiology</i> , 2004, 92, 2725-2737.	0.9	9
346	Chronic Haloperidol Promotes Corticostriatal Long-Term Potentiation by Targeting Dopamine D2L Receptors. <i>Journal of Neuroscience</i> , 2004, 24, 8214-8222.	1.7	90
347	Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. <i>Brain</i> , 2004, 127, 1661-1669.	3.7	78
348	A Critical Interaction between Dopamine D2 Receptors and Endocannabinoids Mediates the Effects of Cocaine on Striatal GABAergic Transmission. <i>Neuropsychopharmacology</i> , 2004, 29, 1488-1497.	2.8	139
349	Abnormal Ca ²⁺ -Calmodulin-Dependent Protein Kinase II Function Mediates Synaptic and Motor Deficits in Experimental Parkinsonism. <i>Journal of Neuroscience</i> , 2004, 24, 5283-5291.	1.7	136
350	The Project for a Scientific Psychology (1895): a Freudian anticipation of LTP-memory connection theory. <i>Brain Research Reviews</i> , 2004, 46, 310-314.	9.1	24
351	Early ionic and membrane potential changes caused by the pesticide rotenone in striatal cholinergic interneurons. <i>Experimental Neurology</i> , 2004, 185, 169-181.	2.0	20
352	Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases. <i>Progress in Neurobiology</i> , 2004, 74, 271-300.	2.8	139
353	Induction of corticostriatal LTP by 3-nitropropionic acid requires the activation of mGluR1/PKC pathway. <i>Neuropharmacology</i> , 2004, 46, 761-769.	2.0	18
354	Differential contribution of dopamine D2S and D2L receptors in the modulation of glutamate and GABA transmission in the striatum. <i>Neuroscience</i> , 2004, 129, 157-166.	1.1	77
355	Inhibition of mitochondrial complex II alters striatal expression of genes involved in glutamatergic and dopaminergic signaling: possible implications for Huntington's disease. <i>Neurobiology of Disease</i> , 2004, 15, 407-414.	2.1	24
356	Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease. <i>Molecular and Cellular Neurosciences</i> , 2004, 25, 9-20.	1.0	47
357	Brain excitability changes in the relapsing and remitting phases of multiple sclerosis: a study with transcranial magnetic stimulation. <i>Clinical Neurophysiology</i> , 2004, 115, 956-965.	0.7	106
358	The Concept of 'Neuroprotection' in Neurological Diseases. <i>Current Neuropharmacology</i> , 2004, 2, 261-263.	1.4	0
359	Synaptic plasticity in the ischaemic brain. <i>Lancet Neurology</i> , The, 2003, 2, 622-629.	4.9	139
360	Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. <i>Annals of Neurology</i> , 2003, 53, 693-702.	2.8	125

#	ARTICLE	IF	CITATIONS
361	Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. <i>Journal of Neurochemistry</i> , 2003, 85, 1018-1025.	2.1	145
362	Voltage-dependent membrane potential oscillations of rat striatal fast-spiking interneurons. <i>Journal of Physiology</i> , 2003, 549, 121-130.	1.3	75
363	Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. <i>Nature Neuroscience</i> , 2003, 6, 501-506.	7.1	791
364	Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study. <i>Experimental Neurology</i> , 2003, 182, 461-469.	2.0	18
365	Corticostriatal LTP requires combined mGluR1 and mGluR5 activation. <i>Neuropharmacology</i> , 2003, 44, 8-16.	2.0	86
366	Targeting striatal cholinergic interneurons in Parkinson's disease: Focus on metabotropic glutamate receptors. <i>Neuropharmacology</i> , 2003, 45, 45-56.	2.0	85
367	Excitation by dopamine of rat subthalamic nucleus neurones in vitro—a direct action with unconventional pharmacology. <i>Neuroscience</i> , 2003, 116, 157-166.	1.1	35
368	Ionotropic glutamate receptors: still a target for neuroprotection in brain ischemia? insights from in vitro studies. <i>Neurobiology of Disease</i> , 2003, 12, 82-88.	2.1	40
369	Dopamine, Acetylcholine and Nitric Oxide Systems Interact to Induce Corticostriatal Synaptic Plasticity. <i>Reviews in the Neurosciences</i> , 2003, 14, 207-16.	1.4	110
370	Distinct Roles of D ₁ and D ₅ Dopamine Receptors in Motor Activity and Striatal Synaptic Plasticity. <i>Journal of Neuroscience</i> , 2003, 23, 8506-8512.	1.7	213
371	Receptor Subtypes Involved in the Presynaptic and Postsynaptic Actions of Dopamine on Striatal Interneurons. <i>Journal of Neuroscience</i> , 2003, 23, 6245-6254.	1.7	209
372	Activation of Î²1-Adrenoceptors Excites Striatal Cholinergic Interneurons through a cAMP-Dependent, Protein Kinase-Independent Pathway. <i>Journal of Neuroscience</i> , 2003, 23, 5272-5282.	1.7	45
373	Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. <i>Brain</i> , 2002, 125, 2635-2645.	3.7	76
374	Tissue plasminogen activator is required for striatal post-ischemic synaptic potentiation. <i>NeuroReport</i> , 2002, 13, 115-118.	0.6	12
375	Post-ischaemic long-term synaptic potentiation in the striatum: a putative mechanism for cell type-specific vulnerability. <i>Brain</i> , 2002, 125, 844-860.	3.7	64
376	Experimental Parkinsonism Modulates Multiple Genes Involved in the Transduction of Dopaminergic Signals in the Striatum. <i>Neurobiology of Disease</i> , 2002, 10, 387-395.	2.1	43
377	Dopamine Excites Fast-Spiking Interneurons in the Striatum. <i>Journal of Neurophysiology</i> , 2002, 87, 2190-2194.	0.9	140
378	Endogenous Dopamine Amplifies Ischemic Long-Term Potentiation via D1 Receptors. <i>Stroke</i> , 2002, 33, 2978-2984.	1.0	27

#	ARTICLE	IF	CITATIONS
379	Metabotropic Glutamate 2 Receptors Modulate Synaptic Inputs and Calcium Signals in Striatal Cholinergic Interneurons. <i>Journal of Neuroscience</i> , 2002, 22, 6176-6185.	1.7	67
380	Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic Transmission. <i>Journal of Neuroscience</i> , 2002, 22, 6900-6907.	1.7	303
381	Cocaine and Amphetamine Depress Striatal GABAergic Synaptic Transmission through D2 Dopamine Receptors. <i>Neuropsychopharmacology</i> , 2002, 26, 164-175.	2.8	78
382	Dopamine D2 Receptor-Mediated Inhibition of Dopaminergic Neurons in Mice Lacking D2L Receptors. <i>Neuropsychopharmacology</i> , 2002, 27, 723-726.	2.8	79
383	Activation of dopamine D1-like receptors excites LTS interneurons of the striatum. <i>European Journal of Neuroscience</i> , 2002, 15, 2049-2052.	1.2	69
384	Tissue plasminogen activator is required for corticostriatal long-term potentiation. <i>European Journal of Neuroscience</i> , 2002, 16, 713-721.	1.2	52
385	Dopamine-Dependent Long-Term Potentiation Induced by 3-Nitropropionic Acid in Striatal Medium Spiny Neurons. <i>Advances in Behavioral Biology</i> , 2002, , 187-190.	0.2	0
386	Impaired Excitatory Transmission in the Striatum of Rats Chronically Intoxicated with Manganese. <i>Experimental Neurology</i> , 2001, 172, 469-476.	2.0	29
387	Selective Blockade of Type-1 Metabotropic Glutamate Receptors Induces Neuroprotection by Enhancing Gabaergic Transmission. <i>Molecular and Cellular Neurosciences</i> , 2001, 17, 1071-1083.	1.0	92
388	A Synaptic Mechanism Underlying the Behavioral Abnormalities Induced by Manganese Intoxication. <i>Neurobiology of Disease</i> , 2001, 8, 419-432.	2.1	72
389	Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. <i>Neuroscience</i> , 2001, 106, 579-587.	1.1	292
390	Ionic mechanisms underlying differential vulnerability to ischemia in striatal neurons. <i>Progress in Neurobiology</i> , 2001, 63, 687-696.	2.8	59
391	Functional coexpression of excitatory mGluR1 and mGluR5 on striatal cholinergic interneurons. <i>Neuropharmacology</i> , 2001, 40, 460-463.	2.0	55
392	Selective involvement of mGlu1 receptors in corticostriatal LTD. <i>Neuropharmacology</i> , 2001, 40, 839-846.	2.0	104
393	Inhibition of Mitochondrial Complex II Induces a Long-Term Potentiation of NMDA-Mediated Synaptic Excitation in the Striatum Requiring Endogenous Dopamine. <i>Journal of Neuroscience</i> , 2001, 21, 5110-5120.	1.7	152
394	Stimulation of Nitric Oxideâ€“cGMP Pathway Excites Striatal Cholinergic Interneurons via Protein Kinase G Activation. <i>Journal of Neuroscience</i> , 2001, 21, 1393-1400.	1.7	44
395	An abnormal striatal synaptic plasticity may account for the selective neuronal vulnerability in Huntington's disease. <i>Neurological Sciences</i> , 2001, 22, 61-62.	0.9	14
396	Dopaminergic control of synaptic plasticity in the dorsal striatum. <i>European Journal of Neuroscience</i> , 2001, 13, 1071-1077.	1.2	319

#	ARTICLE	IF	CITATIONS
397	Adenosine-mediated inhibition of striatal GABAergic synaptic transmission during in vitro ischaemia. <i>Brain</i> , 2001, 124, 1855-1865.	3.7	38
398	Activation of metabotropic glutamate receptor subtype 1/protein kinase C/mitogen-activated protein kinase pathway is required for postischemic long-term potentiation in the striatum. <i>Molecular Pharmacology</i> , 2001, 60, 808-15.	1.0	32
399	Receptor and post-receptor mechanisms of ischemic long-term potentiation in the striatum. <i>Functional Neurology</i> , 2001, 16, 149-52.	1.3	3
400	Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. <i>European Journal of Neuroscience</i> , 2000, 12, 1002-1012.	1.2	158
401	Involvement of Intracellular Calcium Stores during Oxygen/Glucose Deprivation in Striatal Large Aspiny Interneurons. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 839-846.	2.4	28
402	Cell-type specificity of mGluR activation in striatal neuronal subtypes. <i>Amino Acids</i> , 2000, 19, 119-129.	1.2	28
403	Dopamine and cAMP-Regulated Phosphoprotein 32 kDa Controls Both Striatal Long-Term Depression and Long-Term Potentiation, Opposing Forms of Synaptic Plasticity. <i>Journal of Neuroscience</i> , 2000, 20, 8443-8451.	1.7	337
404	Activation of D2-Like Dopamine Receptors Reduces Synaptic Inputs to Striatal Cholinergic Interneurons. <i>Journal of Neuroscience</i> , 2000, 20, RC69-RC69.	1.7	144
405	Is Pharmacological Neuroprotection Dependent on Reduced Glutamate Release?. <i>Stroke</i> , 2000, 31, 766-773.	1.0	71
406	Cellular factors controlling neuronal vulnerability in the brain. <i>Neurology</i> , 2000, 55, 1249-1255.	1.5	111
407	Electrophysiology of Sipatrigine: A Lamotrigine Derivative Exhibiting Neuroprotective Effects. <i>Experimental Neurology</i> , 2000, 162, 171-179.	2.0	11
408	Acetylcholine-mediated modulation of striatal function. <i>Trends in Neurosciences</i> , 2000, 23, 120-126.	4.2	400
409	Synaptic transmission in the striatum: from plasticity to neurodegeneration. <i>Progress in Neurobiology</i> , 2000, 61, 231-265.	2.8	254
410	Electrophysiology of dopamine in normal and denervated striatal neurons. <i>Trends in Neurosciences</i> , 2000, 23, S57-S63.	4.2	145
411	Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?. <i>Annals of Neurology</i> , 2000, 47, S60-8; discussion S68-9.	2.8	79
412	Glutamate-Triggered Events Inducing Corticostriatal Long-Term Depression. <i>Journal of Neuroscience</i> , 1999, 19, 6102-6110.	1.7	87
413	A Critical Role of the Nitric Oxide/cGMP Pathway in Corticostriatal Long-Term Depression. <i>Journal of Neuroscience</i> , 1999, 19, 2489-2499.	1.7	218
414	Unilateral Dopamine Denervation Blocks Corticostriatal LTP. <i>Journal of Neurophysiology</i> , 1999, 82, 3575-3579.	0.9	214

#	ARTICLE	IF	CITATIONS
415	Electrophysiological Recordings and Calcium Measurements in Striatal Large Aspiny Interneurons in Response to Combined O ₂ /Glucose Deprivation. <i>Journal of Neurophysiology</i> , 1999, 81, 2508-2516.	0.9	46
416	An in vitro electrophysiological study on the effects of phenytoin, lamotrigine and gabapentin on striatal neurons. <i>British Journal of Pharmacology</i> , 1999, 126, 689-696.	2.7	65
417	Permissive role of interneurons in corticostriatal synaptic plasticity. <i>Brain Research Reviews</i> , 1999, 31, 1-5.	9.1	86
418	Modulation of gene expression following long-term synaptic depression in the striatum. <i>Molecular Brain Research</i> , 1999, 72, 89-96.	2.5	26
419	Activation of M1-like muscarinic receptors is required for the induction of corticostriatal LTP. <i>Neuropharmacology</i> , 1999, 38, 323-326.	2.0	118
420	Neurophysiology of Parkinson's disease: from basic research to clinical correlates. <i>Clinical Neurophysiology</i> , 1999, 110, 2006-2013.	0.7	17
421	Metabotropic Glutamate Receptors and Cell-Type-Specific Vulnerability in the Striatum: Implication for Ischemia and Huntington's Disease. <i>Experimental Neurology</i> , 1999, 158, 97-108.	2.0	99
422	Sodium Influx Plays a Major Role in the Membrane Depolarization Induced by Oxygen and Glucose Deprivation in Rat Striatal Spiny Neurons. <i>Stroke</i> , 1999, 30, 171-179.	1.0	70
423	Muscarinic IPSPs in rat striatal cholinergic interneurons. <i>Journal of Physiology</i> , 1998, 510, 421-427.	1.3	83
424	Endogenous ACh enhances striatal NMDA-responses via M1-like muscarinic receptors and PKC activation. <i>European Journal of Neuroscience</i> , 1998, 10, 2887-2895.	1.2	133
425	Hypoglycemia, Hypoxia, and Ischemia in a Corticostriatal Slice Preparation: Electrophysiologic Changes and Ascorbyl Radical Formation. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1998, 18, 868-875.	2.4	19
426	Blockade of M2-like muscarinic receptors enhances long-term potentiation at corticostriatal synapses. <i>European Journal of Neuroscience</i> , 1998, 10, 3020-3023.	1.2	89
427	Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: Implications for ischemia and Huntington's disease. <i>Annals of Neurology</i> , 1998, 43, 586-597.	2.8	126
428	Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons. <i>Neuropharmacology</i> , 1998, 37, 1063-1070.	2.0	39
429	Activation of Group III Metabotropic Glutamate Receptors Depresses Glutamatergic Transmission at Corticostriatal Synapse. <i>Neuropharmacology</i> , 1997, 36, 845-851.	2.0	99
430	Opposite Membrane Potential Changes Induced by Glucose Deprivation in Striatal Spiny Neurons and in Large Aspiny Interneurons. <i>Journal of Neuroscience</i> , 1997, 17, 1940-1949.	1.7	65
431	Endogenous Adenosine Mediates the Presynaptic Inhibition Induced by Aglycemia at Corticostriatal Synapses. <i>Journal of Neuroscience</i> , 1997, 17, 4509-4516.	1.7	67
432	Abnormal Synaptic Plasticity in the Striatum of Mice Lacking Dopamine D2 Receptors. <i>Journal of Neuroscience</i> , 1997, 17, 4536-4544.	1.7	279

#	ARTICLE	IF	CITATIONS
433	A Possible Mechanism for the Aglycemia-Induced Depression of Glutamatergic Excitation in the Striatum. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1997, 17, 1121-1126.	2.4	14
434	Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. <i>British Journal of Pharmacology</i> , 1997, 120, 1007-1014.	2.7	193
435	Synaptic plasticity and physiological interactions between dopamine and glutamate in the striatum. <i>Neuroscience and Biobehavioral Reviews</i> , 1997, 21, 519-523.	2.9	96
436	Role of Ca ²⁺ in striatal LTD and LTP. <i>Seminars in Neuroscience</i> , 1996, 8, 321-328.	2.3	28
437	Clarity on Cannabinoid-Based Products in Medicine. <i>European Medical Journal Neurology</i> , 0, , .	0.0	1
438	Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 0, , 1-8.	2.3	5
439	Usability of an application device for nabiximols oromucosal spray in patients with upper limb impaired multiple sclerosis. <i>Neurodegenerative Disease Management</i> , 0, , .	1.2	0